This paper is in the following e-collection/theme issue:

RCTs - Protocols/Proposals (eHealth) (696) mHealth for Symptom and Disease Monitoring, Chronic Disease Management (1783) Prescribable Digital Interventions (Digital Therapeutics) (47) Web-based and Mobile Health Interventions (4140) Telehealth and Telemonitoring (2142)

Published on in Vol 15 (2026)

Preprints (earlier versions) of this paper are available at https://preprints.jmir.org/preprint/75306, first published .
Evaluating the Safety and Performance of the KidneYou App for Chronic Kidney Disease: Protocol for an Italian Multicenter, Randomized, Open-Label, Premarket Study

Evaluating the Safety and Performance of the KidneYou App for Chronic Kidney Disease: Protocol for an Italian Multicenter, Randomized, Open-Label, Premarket Study

Evaluating the Safety and Performance of the KidneYou App for Chronic Kidney Disease: Protocol for an Italian Multicenter, Randomized, Open-Label, Premarket Study

Authors of this article:

Cesira Cafiero1 Author Orcid Image ;   Marco Gnesi2 Author Orcid Image ;   Anna Rita Maurizi3 Author Orcid Image ;   Andreana Foresta4 Author Orcid Image ;   Massimo Beccaria4 Author Orcid Image ;   Giorgia Campilongo5 Author Orcid Image ;   Marco Fiorentino5 Author Orcid Image ;   Paola Maria Acquaviva1 Author Orcid Image ;   Francesca Mastromauro6 Author Orcid Image ;   Marco Gorini7 Author Orcid Image ;   Loreto Gesualdo5 Author Orcid Image
Article Authors Cited by Tweetations Metrics

Cesira Cafiero   1 , PhD ;   Marco Gnesi   2 , PhD ;   Anna Rita Maurizi   3 , MD, PhD ;   Andreana Foresta   4 , MSc ;   Massimo Beccaria   4 , MSc ;   Giorgia Campilongo   5 , MD ;   Marco Fiorentino   5 , MD, PhD ;   Paola Maria Acquaviva   1 , MSc ;   Francesca Mastromauro   6 , MSc ;   Marco Gorini   7 , MSc, EMBA ;   Loreto Gesualdo   5 , MD

1 Nephrology, Dialysis and Transplantation Unit of the University Hospital Consortium, Bari, Italy

2 Medical Evidence, Biopharmaceuticals Medical, AstraZeneca, Milan, Italy

3 Medical Affairs, Biopharmaceuticals Medical, AstraZeneca, Milan, Italy

4 Advice Pharma Group Srl, Milan, Italy

5 Department of Precision and Regenerative Medicine and Ionian Area (DiMePre-J), Nephrology Dialysis and Transplantation Unit, University of Bari Aldo Moro, Bari, BA, Italy

6 Medical Evidence EUCAN, Biopharmaceuticals Medical, AstraZeneca, Milan, Italy

7 Innovation Unit & Business Excellence, AstraZeneca, Milan, Italy

Corresponding Author:

  • Loreto Gesualdo, MD
  • Department of Precision and Regenerative Medicine and Ionian Area (DiMePre-J)
  • Nephrology Dialysis and Transplantation Unit, University of Bari Aldo Moro
  • Piazza Umberto I
  • Bari, BA 70121
  • Italy
  • Phone: 39 3204394546
  • Email: Loreto.gesualdo@uniba.it